GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » COGS-to-Revenue

Lumos Diagnostics Holdings (ASX:LDX) COGS-to-Revenue : 0.32 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings COGS-to-Revenue?

Lumos Diagnostics Holdings's Cost of Goods Sold for the six months ended in Jun. 2024 was A$4.07 Mil. Its Revenue for the six months ended in Jun. 2024 was A$12.60 Mil.

Lumos Diagnostics Holdings's COGS to Revenue for the six months ended in Jun. 2024 was 0.32.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lumos Diagnostics Holdings's Gross Margin % for the six months ended in Jun. 2024 was 67.69%.


Lumos Diagnostics Holdings COGS-to-Revenue Historical Data

The historical data trend for Lumos Diagnostics Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings COGS-to-Revenue Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
COGS-to-Revenue
0.62 0.43 0.36

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
COGS-to-Revenue Get a 7-Day Free Trial 0.65 0.51 0.36 0.48 0.32

Lumos Diagnostics Holdings COGS-to-Revenue Calculation

Lumos Diagnostics Holdings's COGS to Revenue for the fiscal year that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=6.073 / 16.763
=0.36

Lumos Diagnostics Holdings's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.07 / 12.598
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Diagnostics Holdings  (ASX:LDX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lumos Diagnostics Holdings's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 4.07 / 12.598
=67.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Lumos Diagnostics Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Diagnostics Holdings Business Description

Traded in Other Exchanges
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings Headlines

No Headlines